Quality of Life and Survivorship in Lymphoma

Rosenthal, Allison

doi:10.1007/s11912-022-01283-3

Cited by 10 publications

(6 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 12 A systematic review also observed that among patients with HL, several aspects of HRQoL including emotional effects can be persistent among patients with lymphoma. 43 Our results are also similar to what we observed in the RCA of the validation of other EORTC measures for patients with chronic lymphocytic leukemia (CLL; ie, QLQ-CLL17) 44 and non-Hodgkin lymphoma (NHL; ie, QLQ-NHL-HG29 and QLQ-NHL-LG20).…”

Section: Discussionsupporting

confidence: 87%

International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27

Oerlemans,

Efficace,

Shamieh

et al. 2023

Blood Advances

View full text Add to dashboard Cite

Hodgkin lymphoma (HL) has become one of the most curable cancers. Therefore, rigorous assessment of health-related quality of life (HRQoL) and symptom burden of these patients is essential to support informed clinical decisions. This paper reports the final results of an international study by the European Organisation for Research and Treatment of Cancer (EORTC) to develop a HRQoL disease-specific measure for these patients: the EORTC QLQ-HL27. Patients with a confirmed diagnosis of HL (N=381) were enrolled from 12 countries and completed the EORTC QLQ-C30, QLQ-HL27 and a debriefing questionnaire at baseline (any time after diagnosis). A subset completed a retest (N=126) or responsiveness to change analyses (RCA) second measurement (N=98). Psychometrics were evaluated. Confirmatory factor analysis showed an acceptable fit of the 27 items of the QLQ-HL27 on its four scales (symptom burden, physical condition/fatigue, emotional impact, and worries about health/functioning). Test-retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results. Symptom burden and fatigue was higher among patients on treatment (with 36-83% reporting at least a little problems) compared to those after treatment (19-61% reporting at least a little problems). Prevalence of worries about health and functioning (reporting at least a little worry) was similar for patients on treatment (51-81%) versus after treatment (52-78%). Implementation of the EORTC QLQ-HL27 in research and clinical applications will increase sensitivity of HRQoL assessment in patients with HL. High quality data generated through use of this questionnaire are expected to facilitate clinical decision making in the HL setting.

show abstract

Section: Discussionsupporting

confidence: 87%

International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27

Oerlemans,

Efficace,

Shamieh

et al. 2023

Blood Advances

View full text Add to dashboard Cite

show abstract

“…NHL patients experience high rates of financial toxicity and physical symptoms. Fatigue, in particular, can be severe, debilitating, and persistent even in survivorship [91][92][93]. More than 50% of NHL patients experience substantial treatment toxicities and high care utilization at the end of life [94].…”

Section: Symptom Burden and Palliative Care Needsmentioning

confidence: 99%

Advancing Palliative Care Integration in Hematology: Building Upon Existing Evidence

Robbins-Welty

Webb

Shalev

et al. 2023

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Patients with hematologic malignancies and their families are among the most distressed of all those with cancer. Despite high palliative care-related needs, the integration of palliative care in hematology is underdeveloped. The evidence is clear that the way forward Current Treatment Options in Oncology includes standard-of-care PC integration into routine hematologic malignancy care to improve patient and caregiver outcomes. As the PC needs for patients with blood cancer vary significantly by disease, a disease-specific PC integration strategy is needed, allowing for serious illness care interventions to be individualized to the specific needs of each patient and situation.

show abstract

“…It is known from other tumor entities, that some cancer survivors recover without constraints, while others suffer physical, psychological, financial or social impairments (Medicine and Council 2006;Stein et al 2008). While survivorship programs have already been established as part of the clinical routine in other tumor entities such as breast cancer, prostate cancer, and lymphoma, it is uncommon in metastasized melanoma patients (Shapiro 2018;Rosenthal 2022;Pinto et al 2022;Shrem et al 2022). The term "long-term survivors" is often used for patients who were diagnosed more than five years ago.…”

Section: Introductionmentioning

confidence: 99%

Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017

Reitmajer,

Leiter,

Nanz

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Since the introduction of immune checkpoint inhibitors (ICI) and targeted therapies (TT), survival rates of metastatic melanoma patients have increased significantly and complete remissions are no longer rarities. Consequently, there is an increasing number of long-term survivors who have not yet been comprehensively characterized. Methods We included melanoma patients who entered stage IV between 2014 and 2017 and survived at least 5 years after entering stage IV. Descriptive statistics were performed to characterize the applied systemic therapies, response rates and to report which of these patients are still alive today. Results 640 patients entered stage IV at the University Hospital Tuebingen. Of these, 207 patients (32%) were still alive at least 5 years after entering stage IV. Details of applied therapies and response rates were available in 176 patients (85%). About 90% of patients (n = 159) were still alive at the time of analysis. Median survival since first stage IV diagnosis was 6.0 years (range 5–9 years). An impressive majority of patients (n = 146, 83%) were no longer receiving systemic therapy at the time of evaluation. Complete remission under first line systemic therapy was seen in 36% of the patients. Conclusion This dataset comprises the largest available cohort of long-term surviving stage IV melanoma patients. Since 90% of patients in our cohort are still alive today, we expect an increasing number of long-term survivors in the future. Our data indicate the need for specific follow-up programs addressing the needs of long-term survivors.

show abstract

Quality of Life and Survivorship in Lymphoma

Cited by 10 publications

References 62 publications

International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27

International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27

Advancing Palliative Care Integration in Hematology: Building Upon Existing Evidence

Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017

Contact Info

Product

Resources

About